Quick Answer
Celldex Therapeutics, Inc. reported Net Income of -$258.76 million for fiscal year 2025.
Celldex Therapeutics, Inc. Net Income — Annual History
| Fiscal Year | Net Income | YoY Change |
|---|---|---|
| 2025 | -$258.76M | -63.9% |
| 2024 | -$157.86M | -11.6% |
| 2023 | -$141.43M | — |
Quarterly Net Income
| Quarter Ending | Net Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$67.04M | -59.2% | -18.5% |
| June 30, 2025 | -$56.60M | -57.9% | -5.2% |
| March 31, 2025 | -$53.80M | -64.0% | -27.7% |
| September 30, 2024 | -$42.12M | — | -17.5% |
| June 30, 2024 | -$35.84M | — | -9.2% |
| March 31, 2024 | -$32.81M | — | — |
- Celldex Therapeutics, Inc. showed a decrease of -63.9% in Net Income compared to the prior fiscal year.
- Over the 2023–2025 period, Celldex Therapeutics, Inc.’s net income has declined by 83.0% (from -$141.43 million to -$258.76 million).
- The most recent figure is from Celldex Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 25, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: